FY23 Breast Cancer Research Program (BCRP)

Breakthrough Award Levels 1 and 2 (BTA12)

$450K - $2M / 3 or 4 years

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer.

Era of Hope Scholar Award (EOHS)

$3M / 4 years

The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.

As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the demonstrated ability of the individual named as the Principal Investigator (PI) in the application to go beyond conventional thinking in their field and the innovative contribution that the PI can make toward ending breast cancer. The application should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

Clinical Research Extension Award (CREA)

Single PI: $5M / 4 years
Partnering PI Option: $6M / 4 years

The FY23 BCRP Clinical Research Extension Award aims to extend the data collection, followup, and analysis of breast cancer clinical research studies. The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.

NEW for FY23 - Transformative Breast Cancer Consortium Development Award (TBCCDA)

$100K / 1 year

The FY23 Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY23 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s). However, it is not necessary to receive a development award in order to apply for a full consortium award in the future. For FY23, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. Detailed information on the FY23 Transformative Breast Cancer Consortium Award is available under a separate program announcement (HT945-23-BCRP-TBCCA).

Transformative Breast Cancer Consortium Award (TBCCA)

$25M / 4 years

The FY23 Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer. This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer. The transformation intended by the consortium must be in people’s lives, and not in the healthcare or research system.

Breakthrough Award Level 3 (BTA3)

Single PI: $4M / 4 years
Partnering PI Option: $5M / 4 years

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer.

Breakthrough Award Level 4 (BTA4)

$15M / 4 years

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer.

Innovator Award (INNOV)

$7M / 4 years

The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer.